Sarosdy M F, Kledzik G, Lamm D L
Urology. 1982 Jan;19(1):33-6. doi: 10.1016/0090-4295(82)90041-3.
Use of radioimmunoassay (RIA) for determinations of prostatic acid phosphatase has recently received considerable attention because of reported higher sensitivity and specificity than previous enzymatic assays. We have compared the sensitivity and specificity of a commercially available RIA to a highly specific enzymatic assay (thymolphthalein monophosphate) using 37 patients with prostatic cancer and 34 patients with surgically proved benign prostatic hyperplasia. Seventeen of the cancer patients and all 34 of the BPH patients were studied prospectively. We further evaluated specificity by performing the RIA on 25 specimens of bone marrow from patients with nonprostatic disease. Our results indicate the radioimmunoassay is not, at this time, an adequate screening tool, and we question its accuracy in staging patients anymore reliably than by enzymatic assay.
由于据报道放射免疫测定法（RIA）比以往的酶促测定法具有更高的灵敏度和特异性，因此使用该方法测定前列腺酸性磷酸酶最近受到了相当多的关注。我们使用37例前列腺癌患者和34例经手术证实为良性前列腺增生的患者，将一种市售RIA的灵敏度和特异性与一种高特异性酶促测定法（麝香草酚酞单磷酸）进行了比较。对17例癌症患者和所有34例良性前列腺增生患者进行了前瞻性研究。我们通过对25例非前列腺疾病患者的骨髓标本进行RIA进一步评估了特异性。我们的结果表明，目前放射免疫测定法并不是一种足够的筛查工具，而且我们质疑其在对患者进行分期时是否比酶促测定法更准确可靠。
